Beta Bionics (BBNX) reported a Q4 net loss late Tuesday of $2.72 per diluted share.
The company did not provide a year-ago per-share figure.
Analysts polled by Factset expected a loss of $0.90.
Net sales for the quarter ended Dec. 31 were $20.4 million, up from $8.4 million a year earlier.
Analysts surveyed by Factset expected $20.2 million.
The company set full-year 2025 revenue guidance between $80 million and $85 million.
Analysts polled by Factset expect $85.1 million.
Beta Bionics completed its initial public offering on Jan. 30, listing on the Nasdaq Global Market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.